Al's Comment:

 I am very excited about this treatment.   This is the first trial to ever report extended survival in both newly diagnosed and recurrent Glioblastoma.  For newly diagnosed Glioblastoma, 5 year survival more than doubled  from 5.7% to 13%.  And for recurrent Glioblastoma, survival at 20 months and 30 months also doubled, from 9.6% to 15.7% at 24 months and from 5.1% to 11.1% at 30 months.  This is all with a few simple injections which had no side effects. 

Posted on: 11/19/2022

Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma


Click HERE to return to brain tumor news headlines.

Our privacy / cookie policy has changed.
Click HERE to read it!